Meningococcal polysaccharide vaccine, group c - Biologic Drug Details

Summary for meningococcal polysaccharide vaccine, group c

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for meningococcal polysaccharide vaccine, group c Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for meningococcal polysaccharide vaccine, group c Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for meningococcal polysaccharide vaccine, group c Derived from Patent Text Search

No patents found based on company disclosures

Meningococcal polysaccharide vaccine, group c Market Analysis and Financial Projection

Meningococcal Vaccines Market: Dynamics and Financial Trajectory for Meningococcal Polysaccharide and Conjugate Vaccines

Introduction

Meningococcal vaccines are crucial in preventing meningococcal disease, a severe and potentially fatal infection caused by the bacterium Neisseria meningitidis. The market for these vaccines is complex, driven by various factors including technological advancements, government initiatives, and increasing disease prevalence. Here, we will delve into the market dynamics and financial trajectory, with a focus on meningococcal polysaccharide vaccines, particularly those targeting serogroup C.

Market Size and Growth

The global meningococcal vaccines market has been expanding rapidly. In 2023, the market size was valued at USD 3.6 billion and is projected to reach USD 7.2 billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 7.7% during the forecast period[3].

Segmentation of Meningococcal Vaccines

The market is segmented into several types, including polysaccharide vaccines, conjugate vaccines, and combination vaccines. Conjugate vaccines, which link bacterial polysaccharides to carrier proteins, have become the dominant segment due to their enhanced immune response and longer-lasting protection. In 2023, conjugate vaccines accounted for 52.3% of the market share[4].

Serogroup C Vaccines

Demand and Supply

Serogroup C vaccines are a critical component of the meningococcal vaccine market. The demand for these vaccines is driven by their inclusion in national immunization programs (NIPs) in several countries, including the UK, Australia, Belgium, France, Germany, Iceland, Ireland, and the Netherlands. These countries have adopted the serogroup C conjugate vaccine into their NIPs, contributing significantly to the segment's growth[4].

Supply Constraints

The withdrawal of polysaccharide vaccines has created supply constraints, particularly for middle-income countries (MICs) that have relied on these vaccines. The global stockpile, managed by the International Coordinating Group (ICG), faces ongoing supply constraints for C- and W-containing products, which are critical for outbreak response[1].

Financial Trajectory

Revenue Share

The serogroup C segment is expected to witness significant growth over the forecast period. This growth is attributed to the vaccines' high efficacy and increasing integration into national vaccination programs. The conjugate vaccines segment, which includes serogroup C vaccines, is poised for continued growth due to ongoing research and development efforts[4].

Market Drivers

The financial trajectory of meningococcal vaccines, including those targeting serogroup C, is driven by several key factors:

• Increasing Disease Prevalence: The rising incidence of meningococcal disease, particularly in regions like the meningitis belt in sub-Saharan Africa, has highlighted the urgent need for effective vaccination programs[3].
• Government Initiatives: Favorable government initiatives and immunization programs have significantly contributed to market growth. These initiatives include public health campaigns and investments in healthcare infrastructure[4].
• Technological Advancements: Continuous advancements in vaccine technology, such as the development of multivalent and conjugate vaccines, have improved the immune response and protection against meningococcal pathogens[3].

Regional Dynamics

North America and Europe

In these regions, serogroup B is the primary cause of meningococcal disease, but serogroup C vaccines are also widely used. The adoption of serogroup C conjugate vaccines into NIPs in these countries has driven demand and contributed to the market's financial growth[4].

Africa and the Meningitis Belt

The meningitis belt, which includes countries in sub-Saharan Africa, experiences frequent epidemics of meningococcal disease. The introduction of affordable and effective vaccines, such as MenFive® by the Serum Institute of India, has been a significant step in protecting these populations. MenFive® is a multivalent meningococcal conjugate vaccine that protects against serogroups A, C, W, and Y and is expected to be available at an extremely affordable price, making it accessible to those who need it most[2].

Challenges and Opportunities

Supply Chain Issues

The withdrawal of polysaccharide vaccines has reduced country access, particularly for MICs. This has created a gap that conjugate vaccines are trying to fill. However, the supply of conjugate MenACWY vaccines is currently insufficient to meet the growing demand, especially for serogroups C and W[1].

New Product Developments

The prequalification of new multivalent meningococcal conjugate vaccines, such as MenFive®, represents a significant opportunity for improving public health. These vaccines are expected to save thousands of lives every year and are a critical addition to the toolbox for bacterial meningitis prevention and control[2].

Key Takeaways

• Market Growth: The meningococcal vaccines market is expected to grow significantly, reaching USD 7.2 billion by 2032.
• Conjugate Vaccines: Conjugate vaccines dominate the market due to their enhanced immune response and longer-lasting protection.
• Serogroup C: The serogroup C segment is expected to grow rapidly due to its inclusion in national immunization programs and high efficacy.
• Regional Dynamics: Different regions have varying demands based on the prevalent serogroups, with Africa and the meningitis belt being critical areas for vaccination efforts.
• Challenges: Supply chain issues and the need for affordable vaccines remain significant challenges.

FAQs

What is the projected market size for meningococcal vaccines by 2032?

The global meningococcal vaccines market is expected to reach USD 7.2 billion by 2032[3].

Which type of meningococcal vaccine dominates the market?

Conjugate vaccines dominate the market, accounting for 52.3% of the market share in 2023[4].

Why is there a growing demand for serogroup C vaccines?

The growing demand for serogroup C vaccines is driven by their inclusion in national immunization programs and their high efficacy in preventing meningococcal disease[4].

What are the main challenges facing the meningococcal vaccine market?

The main challenges include supply chain issues due to the withdrawal of polysaccharide vaccines and the need for affordable vaccines, especially in low- and middle-income countries[1].

How do government initiatives impact the meningococcal vaccine market?

Government initiatives, such as public health campaigns and investments in healthcare infrastructure, significantly contribute to market growth by increasing vaccination coverage and promoting the use of effective vaccines[4].

Sources

1. WHO Meningococcal Vaccines Public Summary - WHO.
2. Multivalent Meningococcal Meningitis Vaccine from Serum Institute of India Achieves WHO Prequalification - PATH.
3. Meningococcal Vaccines Market to Reach USD 7.2 Billion by 2032 - BioSpace.
4. Meningococcal Vaccines Market: Size, Share, Trends 2032 - Vantage Market Research.
5. A Phase 3, Double-Blind, Randomized, Active Controlled Study to Evaluate the Safety and Immunogenicity of PsA-TT (MenAfriVac) - NITAG Resource.